Quest Diagnostics Incorporated Q1 2026 Earnings Recap

DGX Q1 2026 April 21, 2026

Get alerts when DGX reports next quarter

Quest Diagnostics delivered a robust first quarter with over 9% organic revenue growth and a 13% increase in adjusted EPS, driven by broad-based demand and operational efficiencies.

Earnings Per Share Beat

$2.50 vs $2.37 est.

+5.5% surprise

Revenue Beat

2895000000 vs 2828547000 est.

+2.3% surprise

Market Reaction

1-Day +4.45%

5-Day -0.02%

30-Day -4.26%

See DGX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Organic revenue growth nearly entirely fueled by clinical innovations, new clinical areas like dialysis testing, and strategic collaborations.
Double-digit revenue growth in hospital channels, especially through lab solutions with Corewell Health, complemented by expanding partnerships and new lab openings.
Consumer health revenue surged, supported by strong repeat customer engagement and expanding lab insights integrated into digital health platforms.
Continued leadership in diagnostics for Alzheimer's and cardiometabolic markers, reflecting successful innovation such as the AD-Detect blood test and new biomarker guidelines.
Management raises full-year revenue and EPS guidance, reflecting confidence in sustained momentum and strategic execution.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit DGX on AllInvestView.